LeMaitre Vascular (NASDAQ:LMAT) Releases Earnings Results, Misses Estimates By $0.07 EPS

LeMaitre Vascular (NASDAQ:LMAT) announced its quarterly earnings results on Tuesday. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07), FiscalAI reports. The company had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a return on equity of 15.90% and a net margin of 25.02%.LeMaitre Vascular’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.60 earnings per share.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q2 organic sales grew 10%, with growth of 12% excluding the temporary catheter recall comparison; operating income rose 26%, EPS increased 23% to $0.74, and operating margin reached a record 29%.
• Artegraft was the fastest-growing product, with sales up 34% and representing 21% of revenue. International sales are expected to reach $11 million in 2026 versus $4 million in 2025, supported by additional country approvals, longer graft sizes, and expanded commercial infrastructure.
• The company reported strong profitability and expansion in Europe, where localized warehouses and sales operations are contributing to significant shipping savings and year-over-year gross-margin gains of roughly 5 to 9 percentage points.
• Full-year revenue guidance was reduced to $276.3 million and organic growth to 11%, reflecting a stronger U.S. dollar, continued Middle East-related export delays, and slower-than-expected cardiac allograft growth because of supply constraints. Operating income guidance was lowered to $76.8 million as the revenue shortfall flows through.
• RestoreFlow and other cardiac allografts remain supply constrained, while the FDA identified additional quality-system observations at the New Jersey facility. The company says production and shipments have not been disrupted, but the QuickStitch project may now require a clinical trial, extending its timeline from quarters to years.

LeMaitre Vascular Price Performance

Shares of LMAT traded up $0.94 during trading hours on Thursday, reaching $79.94. The company had a trading volume of 317,388 shares, compared to its average volume of 268,752. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. LeMaitre Vascular has a 12-month low of $78.65 and a 12-month high of $118.01. The firm has a 50 day simple moving average of $97.08 and a 200-day simple moving average of $99.99. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 28.08, a PEG ratio of 2.94 and a beta of 0.53.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 36.90%.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the transaction, the insider directly owned 3,749 shares of the company’s stock, valued at approximately $401,143. This trade represents a 43.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 27,881 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the sale, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.40% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

Several institutional investors and hedge funds have recently modified their holdings of LMAT. Goldman Sachs Group Inc. raised its holdings in LeMaitre Vascular by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after acquiring an additional 231,157 shares during the last quarter. Millennium Management LLC grew its position in shares of LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after purchasing an additional 115,141 shares during the period. First Trust Advisors LP grew its position in shares of LeMaitre Vascular by 13.4% in the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after purchasing an additional 111,193 shares during the period. Geode Capital Management LLC increased its stake in LeMaitre Vascular by 20.1% in the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after purchasing an additional 105,921 shares during the last quarter. Finally, Algert Global LLC boosted its stake in LeMaitre Vascular by 356.3% in the 3rd quarter. Algert Global LLC now owns 66,268 shares of the medical instruments supplier’s stock worth $5,799,000 after buying an additional 51,744 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

More LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: LeMaitre reported Q2 revenue growth of 9.6% year over year to $70.38 million, while earnings increased to $0.74 per share from $0.60 a year earlier. The company also declared a quarterly dividend of $0.25 per share, equivalent to an approximately 1.1% annualized yield. LeMaitre Q2 2026 Financial Results
• Neutral Sentiment: Analysts now give LMAT an average “Hold” rating. Wells Fargo lowered its price target from $104 to $94 while maintaining an “equal weight” rating; the revised target still implies potential upside from recent levels. Average Hold Rating
• Negative Sentiment: Q2 adjusted earnings of $0.74 per share missed the $0.81 consensus estimate, and revenue of $70.38 million was below expectations of $71.47 million. The earnings shortfall, despite continued year-over-year growth, has prompted investor selling. Q2 Earnings and Revenues Lag Estimates
• Negative Sentiment: Management reduced its outlook: full-year 2026 EPS guidance of $2.84–$2.94 and revenue guidance of $274.3–$278.3 million are below consensus estimates of $3.00 and $279.9 million. Third-quarter EPS and revenue guidance also trail analyst expectations. Financial Results and Guidance
• Negative Sentiment: Barrington Research downgraded LMAT from “outperform” to “market perform,” adding to concerns about slower-than-expected earnings momentum. Analyst Downgrade

Analysts Set New Price Targets

A number of research analysts recently issued reports on LMAT shares. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Citizens Jmp raised their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular currently has a consensus rating of “Hold” and an average price target of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.